Inability to Recruit Adolescents for a Vaping Cessation Clinical Trial Within a Large Pediatric Health System

Jenssen, Brian P.; Hannan, Chloe; Kelly, Mary Kate; Ylioja, Thomas; Schnoll, Robert A.; Fiks, Alexander G.

doi:10.1093/ntr/ntab034

Cited by 7 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Screening question for EVALI is paramount, but a recent study showed that screening questions may not identify youth ecigarette users effectively. 18 We would also argue that follow-up with a pulmonologist is essential as there may be ongoing signs and symptoms of respiratory compromise well after the treatment and resolution of EVALI. Our cases illustrate that PFTs obtained at followup pulmonology outpatient visits proved valuable in showing bronchodilator reversibility in some patients, thereby aiding in asthma management and continuity of care.…”

Section: Discussionmentioning

confidence: 99%

“…It is paramount that accurate screening questions with regard to e‐cigarette use are implemented to discern EVALI from COVID‐19 as presenting symptoms and imaging may be similar. Screening question for EVALI is paramount, but a recent study showed that screening questions may not identify youth e‐cigarette users effectively 18 . We would also argue that follow‐up with a pulmonologist is essential as there may be ongoing signs and symptoms of respiratory compromise well after the treatment and resolution of EVALI.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adolescent e‐cigarette or vaping product use‐associated lung injury: A case series and review of the literature

Singh¹

2022

Pediatric Pulmonology

View full text Add to dashboard Cite

Background: Adolescent e-cigarette or vaping product use-associated lung injury (EVALI) has increased in prevalence, and while cases describing various pulmonary manifestations have been reported, reports on the presentations and outcomes in teenage patients are sparse. Methods:We retrospectively describe eight EVALI patients with different presentations, laboratory and imaging findings, treatment, and concomitant diagnoses.We review the literature and describe how our analysis adds to the literature.Findings: Eight males, aged 15−18 years of age presented with various symptoms.Four patients were Caucasian while four were of Hispanic origin. All patients presented with respiratory symptoms; six also had GI symptoms; five were hypoxemic; all but one patient admitted to using products containing tetrahydrocannabinol (THC). All patients had changes on imaging with ground-glass opacities. One patient underwent lung biopsy and bronchoscopy showing eosinophilic pneumonia. All patients received antimicrobial therapies without improvement until systemic steroids were administered. Six patients underwent pulmonary function testing, and five required medications for newly diagnosed persistent asthma. One patient developed pulmonary hypertension, which resolved after treatment. One patient required noninvasive ventilation. No patients were positive for SARS-CoV2. Two had coinfections with other microbes. Five patients required escalation of asthma therapies at follow-up with pulmonology.Conclusion: This analysis of eight adolescent males hospitalized for EVALI highlights the unpredictable spectrum of disease presentation and management. These patients can be misdiagnosed without proper screening and may have residual respiratory complications necessitating outpatient management by a pulmonologist.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%